2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2300

Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2365

Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2368

Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2333

Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance

RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2434

Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2371

Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2053

Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2675

Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2273

Risk of Serious Infections in Offspring According to TNFi Subtypes

Reproductive Issues In Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2393

Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2697

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – ePoster III: Systemic JIA, Fever, & Vasculitis

9:00AM-11:00AM: Abstract Number: 2619

Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2131

Rituximab Safety and Persistence in Patients with Systemic Autoimmune Diseases

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2141

Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2521

Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

SLE – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].